Does Paroxysmal Nocturnal Hemoglobinuria Cause Esophageal Spasm?
Yes, paroxysmal nocturnal hemoglobinuria (PNH) is a recognized cause of esophageal spasm, though this is a symptom of the disease rather than a primary esophageal disorder.
Mechanism and Clinical Presentation
PNH causes esophageal spasm through a specific pathophysiologic mechanism related to intravascular hemolysis. When PNH red blood cells undergo complement-mediated destruction, free hemoglobin is released into the circulation. This free hemoglobin depletes circulating nitric oxide, which is essential for smooth muscle relaxation 1, 2, 3, 4. The resulting smooth muscle dystonia manifests as esophageal spasm, along with other smooth muscle-related symptoms including:
- Abdominal pain
- Erectile dysfunction
- Fatigue
These symptoms are directly attributable to the hemolysis and nitric oxide depletion, not to a primary esophageal motility disorder 2, 3.
Diagnostic Considerations
When evaluating a patient with esophageal spasm, PNH should be considered in the differential diagnosis, particularly when:
- Peripheral blood findings suggest hemolysis: Look for anemia, elevated LDH, elevated indirect bilirubin, low haptoglobin, and reticulocytosis
- Associated symptoms are present: Hemoglobinuria (especially nocturnal or morning), fatigue disproportionate to anemia, abdominal pain, or thrombotic events
- Cytopenias exist: Neutropenia or thrombocytopenia suggesting bone marrow involvement
- Thrombosis occurs in unusual locations: Particularly intra-abdominal thrombosis including hepatic, portal, or mesenteric veins 5, 6
Flow cytometry screening for PNH should be performed in patients with unexplained hemolysis, particularly when combined with esophageal symptoms 7. Testing for CD55 and CD59 deficiency on red blood cells and granulocytes is the diagnostic standard.
Important Clinical Context
The esophageal spasm in PNH differs fundamentally from primary esophageal motility disorders like achalasia or diffuse esophageal spasm 8, 9. In PNH:
- The spasm is secondary to systemic hemolysis and nitric oxide depletion
- It typically improves with treatment of the underlying PNH
- High-resolution manometry may show spastic contractions, but these are functional consequences of the hematologic disease rather than primary motility pathology
Treatment Implications
Complement inhibitors (eculizumab, ravulizumab) are the definitive treatment for PNH and have been shown to significantly reduce hemolysis and improve symptoms including esophageal spasm 1, 2, 4. These medications:
- Reduce intravascular hemolysis by blocking terminal complement activation at C5
- Restore nitric oxide availability by preventing free hemoglobin release
- Improve smooth muscle function throughout the body
- Significantly enhance quality of life measures including fatigue and pain scores
Treating esophageal spasm in PNH with standard approaches for primary motility disorders (calcium channel blockers, nitrates, or myotomy) would be inappropriate and ineffective, as these do not address the underlying complement-mediated hemolysis 1.
Key Clinical Pitfall
Do not mistake PNH-related esophageal spasm for a primary esophageal motility disorder. If a patient presents with esophageal spasm and any suggestion of hemolysis or unexplained cytopenias, screen for PNH with flow cytometry before pursuing invasive esophageal interventions. The presence of hemoglobinuria, particularly if nocturnal or associated with infections/vaccinations, should immediately raise suspicion for PNH 10, 1.